These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33600687)

  • 1. Efficacy and Safety of Inhaled Human Insulin (Exu hera
    White NH; Quattrin T; Aubin LBS; Duggan WT; England RD; Fryburg JS
    J Pediatr Endocrinol Metab; 2020 Oct; 21(6):555-568. PubMed ID: 33600687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of inhaled human insulin (Exubera) compared to subcutaneous insulin in children ages 6 to 11 years with type 1 diabetes mellitus: results of a 3-month, randomized, parallel trial.
    White NH; Quattrin T; St Aubin LB; Duggan WT; England RD; Fryburg JS
    J Pediatr Endocrinol Metab; 2008 Jun; 21(6):555-68. PubMed ID: 18717242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes.
    Skyler JS; Jovanovic L; Klioze S; Reis J; Duggan W;
    Diabetes Care; 2007 Mar; 30(3):579-85. PubMed ID: 17327324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (exubera).
    Norwood P; Dumas R; Cefalu W; Yale JF; England R; Riese R; Teeter J
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2211-4. PubMed ID: 17003088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes.
    Rosenstock J; Cefalu WT; Hollander PA; Belanger A; Eliaschewitz FG; Gross JL; Klioze SS; St Aubin LB; Foyt H; Ogawa M; Duggan WT
    Diabetes Care; 2008 Sep; 31(9):1723-8. PubMed ID: 18535196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of continuous therapy.
    Cefalu WT; Bohannon NJ; Edwin Fineberg S; Teeter JG; Schwartz PF; Reis JM; Krasner AS
    Curr Med Res Opin; 2008 Nov; 24(11):3073-83. PubMed ID: 18828959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.
    Quattrin T; Bélanger A; Bohannon NJ; Schwartz SL;
    Diabetes Care; 2004 Nov; 27(11):2622-7. PubMed ID: 15504996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 1 diabetes: A 3-year randomized controlled trial.
    Skyler JS; Hollander PA; Jovanovic L; Klioze S; Krasner A; Riese RJ; Reis J; Schwartz P; Duggan W;
    Diabetes Res Clin Pract; 2008 Nov; 82(2):238-46. PubMed ID: 18824271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trough insulin levels in bronchoalveolar lavage following inhaled human insulin (Exubera) in patients with diabetes mellitus.
    Mendivil CO; Teeter JG; Finch GL; Schwartz PF; Riese RJ; Brain JD
    Diabetes Technol Ther; 2012 Jan; 14(1):50-8. PubMed ID: 21875362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial.
    Rosenstock J; Cefalu WT; Hollander PA; Klioze SS; Reis J; Duggan WT
    Diabetes Technol Ther; 2009 Nov; 11(11):697-705. PubMed ID: 19905885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.
    Ceglia L; Lau J; Pittas AG
    Ann Intern Med; 2006 Nov; 145(9):665-75. PubMed ID: 17088580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial.
    Fineberg SE; Kawabata T; Finco-Kent D; Liu C; Krasner A
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3287-94. PubMed ID: 15741258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes.
    Hompesch M; Kollmeier A; Rave K; Heinemann L; Mitnick M; Davies S; Strack T
    Diabetes Technol Ther; 2009 May; 11(5):307-13. PubMed ID: 19537357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study.
    Heise T; Bott S; Tusek C; Stephan JA; Kawabata T; Finco-Kent D; Liu C; Krasner A
    Diabetes Care; 2005 Sep; 28(9):2161-9. PubMed ID: 16123484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.
    Hollander PA; Blonde L; Rowe R; Mehta AE; Milburn JL; Hershon KS; Chiasson JL; Levin SR
    Diabetes Care; 2004 Oct; 27(10):2356-62. PubMed ID: 15451900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial.
    Del Prato S; Blonde L; Martinez L; Göke B; Woo V; Millward A; Gomis R; Canovatchel B; Strack T; Lawrence D; Freemantle N;
    Diabet Med; 2008 Jun; 25(6):662-70. PubMed ID: 18435781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics.
    Fountaine R; Milton A; Checchio T; Wei G; Stolar M; Teeter J; Jaeger R; Fryburg D
    Br J Clin Pharmacol; 2008 Jun; 65(6):864-70. PubMed ID: 18477263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial.
    Moses RG; Bartley P; Lunt H; O'Brien RC; Donnelly T; Gall MA; Vesterager A; Wollmer P; Roberts A
    Diabet Med; 2009 Mar; 26(3):260-7. PubMed ID: 19317821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.
    Garg S; Rosenstock J; Silverman BL; Sun B; Konkoy CS; de la Peña A; Muchmore DB
    Diabetologia; 2006 May; 49(5):891-9. PubMed ID: 16506054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.